Home  |  Contact

UniProtKB/Swiss-Prot P04637: Variant p.Leu257Gln

Cellular tumor antigen p53
Gene: TP53
Variant information

Variant position:  257
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Leucine (L) to Glutamine (Q) at position 257 (L257Q, p.Leu257Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (L) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In LFS; germline mutation and in sporadic cancers; somatic mutation.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  257
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  393
The length of the canonical sequence.

Location on the sequence:   MCNSSCMGGMNRRPILTIIT  L EDSSGNLLGRNSFEVRVCAC
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCAC

                              MCNSSCMGGMNRRPILTIITLEDSSGNVLGRNSFEVRVCAC

Rhesus macaque                MCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCAC

Mouse                         MCNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCAC

Rat                           MCNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCAC

Pig                           MCNSSCMGGMNRRPILTIITLEDASGNLLGRNSFEVRVCAC

Bovine                        MCNSSCMGGMNRRPILTIITLEDSCGNLLGRNSFEVRVCAC

Rabbit                        MCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCAC

Sheep                         MCNSSCMGGMNRRPILTIITLEDSRGNLLGRSSFEVRVCAC

Cat                           MCNSSCMGGMNRRPIITIITLEDSNGKLLGRNSFEVRVCAC

Chicken                       MCNSSCMGGMNRRPILTILTLEGPGGQLLGRRCFEVRVCAC

Xenopus laevis                MCNSSCMGGMNRRPILTIITLETPQGLLLGRRCFEVRVCAC

Zebrafish                     MCNSSCMGGMNRRPILTIITLETQEGQLLGRRSFEVRVCAC

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 393 Cellular tumor antigen p53
DNA binding 102 – 292
Region 1 – 320 Interaction with CCAR2
Region 100 – 370 Interaction with HIPK1
Region 100 – 300 Required for interaction with ZNF385A
Region 116 – 292 Interaction with AXIN1
Region 256 – 294 Interaction with E4F1
Metal binding 238 – 238 Zinc
Metal binding 242 – 242 Zinc
Modified residue 269 – 269 Phosphoserine; by AURKB
Mutagenesis 248 – 248 R -> S. Does not induce SNAI1 degradation.
Mutagenesis 269 – 269 S -> A. Abolishes phosphorylation.
Mutagenesis 269 – 269 S -> E. Inhibits strongly its transcriptional activity.
Beta strand 251 – 258


Literature citations

No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.